0001562180-24-000581.txt : 20240124 0001562180-24-000581.hdr.sgml : 20240124 20240124165028 ACCESSION NUMBER: 0001562180-24-000581 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240122 FILED AS OF DATE: 20240124 DATE AS OF CHANGE: 20240124 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Jones David Scott CENTRAL INDEX KEY: 0001779458 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-51122 FILM NUMBER: 24557043 MAIL ADDRESS: STREET 1: C/O EYEPOINT PHARMACEUTICALS, INC., STREET 2: 480 PLEASANT STREET, SUITE A210 CITY: WATERTOWN STATE: MA ZIP: 02472 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: EyePoint Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001314102 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 262774444 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 480 PLEASANT STREET STREET 2: SUITE B300 CITY: WATERTOWN STATE: MA ZIP: 02472 BUSINESS PHONE: 617-926-5000 MAIL ADDRESS: STREET 1: 480 PLEASANT STREET STREET 2: SUITE B300 CITY: WATERTOWN STATE: MA ZIP: 02472 FORMER COMPANY: FORMER CONFORMED NAME: pSivida Corp. DATE OF NAME CHANGE: 20080619 FORMER COMPANY: FORMER CONFORMED NAME: pSivida LTD DATE OF NAME CHANGE: 20050111 4 1 primarydocument.xml PRIMARY DOCUMENT X0508 4 2024-01-22 false 0001314102 EyePoint Pharmaceuticals, Inc. EYPT 0001779458 Jones David Scott C/O EYEPOINT PHARMACEUTICALS, INC. 480 PLEASANT STREET WATERTOWN MA 02472 false true false false SVP & Chief Commercial Officer false Common Stock 2024-01-22 4 M false 28750.00 10.13 A 66712.00 D Common Stock 2024-01-22 4 M false 5416.00 11.47 A 72128.00 D Common Stock 2024-01-22 4 S false 5416.00 22.2373 D 66712.00 D Common Stock 2024-01-22 4 S false 28750.00 22.6871 D 37962.00 D Common Stock 2024-01-23 4 M false 400.00 12.90 A 38362.00 D Common Stock 2024-01-23 4 M false 500.00 3.26 A 38862.00 D Common Stock 2024-01-23 4 S false 400.00 25.00 D 38462.00 D Common Stock 2024-01-23 4 S false 500.00 25.00 D 37962.00 D Stock Option (Right to Buy) 11.47 2024-01-22 4 M false 5416.00 0.00 D 2031-11-01 Common Stock 5416.00 4584.00 D Stock Option (Right to Buy) 10.13 2024-01-22 4 M false 28750.00 0.00 D 2032-02-09 Common Stock 28750.00 31250.00 D Stock Option (Right to Buy) 12.90 2024-01-23 4 M false 400.00 0.00 D 2030-02-28 Common Stock 400.00 24225.00 D Stock Option (Right to Buy) 3.26 2024-01-23 4 M false 500.00 0.00 D 2033-01-05 Common Stock 500.00 91155.00 D The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.00 to $23.00. The reporting person undertakes to provide EyePoint Pharmaceuticals Inc., any security holder of EyePoint Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.00 to $23.04. The reporting person undertakes to provide EyePoint Pharmaceuticals Inc., any security holder of EyePoint Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The option to purchase will vest and become exercisable as follows: 25% at November 1st, 2022 and the remainder ratably, on a monthly basis, over the remaining three years. The option to purchase will vest and become exercisable as follows: 25% at February 9th, 2023 and the remainder ratably, on a monthly basis, over the remaining three years. The option to purchase vests and becomes exercisable ratably in forty-eight monthly installments which began March 28, 2020 The option to purchase vests and becomes exercisable as follows: 25% at January 6th, 2024 and the remainder ratably, on a monthly basis, over the remaining three years. /s/ Ron Honig, Attorney-in-Fact 2024-01-24